In vivo response to remission induction poly-chemotherapy in NOD/SCID/huALL reflects patient risk and outcome

As novel therapeutics are urgently needed for treating acute lymphoblastic leukemia (ALL) we established a poly-agent chemotherapy regimen in our NOD/SCID/huALL xenograft model investigating its effectivity on different patient-derived xenograft (pdx) ALL samples, which further can be used to evaluate novel substances in combination modalities. ALL carrying recipients receiving multi-agent chemotherapy showed a significant delay of post-treatment leukemia reoccurrence compared to vehicle-treated controls in 6 pdx ALL samples and even induced long-term remission in one sample within 30 weeks of monitoring. Previo…